MA39347B2 - Protéines de fusion d'uti - Google Patents

Protéines de fusion d'uti

Info

Publication number
MA39347B2
MA39347B2 MA39347A MA39347A MA39347B2 MA 39347 B2 MA39347 B2 MA 39347B2 MA 39347 A MA39347 A MA 39347A MA 39347 A MA39347 A MA 39347A MA 39347 B2 MA39347 B2 MA 39347B2
Authority
MA
Morocco
Prior art keywords
fusion proteins
uti fusion
uti
proteins
producing
Prior art date
Application number
MA39347A
Other languages
English (en)
Other versions
MA39347A1 (fr
Inventor
Aaron Chamberlain
Qiang Liu
Mathias Schmidt
Original Assignee
Takeda Pharmaceuticals Co
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co, Takeda Gmbh filed Critical Takeda Pharmaceuticals Co
Publication of MA39347A1 publication Critical patent/MA39347A1/fr
Publication of MA39347B2 publication Critical patent/MA39347B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des protéines de fusion d'uti, des séquences d'adn pour produire ces protéines, et des compositions pharmaceutiques et des méthodes d'utilisation correspondantes.
MA39347A 2014-02-24 2015-02-23 Protéines de fusion d'uti MA39347B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
PCT/US2015/017152 WO2015127391A1 (fr) 2014-02-24 2015-02-23 Protéines de fusion d'uti

Publications (2)

Publication Number Publication Date
MA39347A1 MA39347A1 (fr) 2018-06-29
MA39347B2 true MA39347B2 (fr) 2020-05-29

Family

ID=52629709

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39347A MA39347B2 (fr) 2014-02-24 2015-02-23 Protéines de fusion d'uti

Country Status (38)

Country Link
US (4) US9856310B2 (fr)
EP (2) EP3110434B1 (fr)
JP (4) JP6574431B2 (fr)
KR (3) KR102722304B1 (fr)
CN (2) CN106232135B (fr)
AR (1) AR101597A1 (fr)
AU (4) AU2015218704B2 (fr)
BR (1) BR112016019390B1 (fr)
CA (2) CA2939639C (fr)
CL (1) CL2016002136A1 (fr)
CR (1) CR20160444A (fr)
CY (1) CY1120997T1 (fr)
DK (1) DK3110434T3 (fr)
DO (1) DOP2016000202A (fr)
EA (2) EA037256B1 (fr)
EC (1) ECSP16076535A (fr)
ES (1) ES2700149T3 (fr)
GE (2) GEP20196970B (fr)
HR (1) HRP20182029T1 (fr)
IL (1) IL247321B (fr)
JO (1) JO3729B1 (fr)
LT (1) LT3110434T (fr)
MA (1) MA39347B2 (fr)
MX (4) MX384070B (fr)
MY (1) MY178774A (fr)
NZ (3) NZ760008A (fr)
PE (1) PE20170257A1 (fr)
PH (1) PH12016501629B1 (fr)
PL (1) PL3110434T3 (fr)
PT (1) PT3110434T (fr)
RS (1) RS58285B1 (fr)
SG (2) SG10201708400QA (fr)
SI (1) SI3110434T1 (fr)
SM (1) SMT201800674T1 (fr)
TW (1) TWI694084B (fr)
UA (1) UA118866C2 (fr)
WO (1) WO2015127391A1 (fr)
ZA (1) ZA201606327B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939639C (fr) * 2014-02-24 2023-01-24 Takeda Gmbh Proteines de fusion d'uti
WO2018226887A1 (fr) 2017-06-07 2018-12-13 Spark Therapeutics, Inc. Agents d'activation destinés à la transfection de cellules et/ou la production de vecteur raav améliorées
WO2020106881A1 (fr) * 2018-11-20 2020-05-28 Diamedica Inc. Polypeptides d'ulinastatine modifiés
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
JP7778077B2 (ja) * 2020-03-05 2025-12-01 ダイアメディカ ユーエスエー インコーポレイテッド ウリナスタチンポリペプチド
WO2022165031A1 (fr) * 2021-01-29 2022-08-04 DiaMedica USA Inc. Polypeptides d'ulinastatine pour le traitement de maladies
CN116903721A (zh) * 2023-06-16 2023-10-20 成都佩德生物医药有限公司 多肽pdbpe-001、其药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
ATE114332T1 (de) 1989-05-13 1994-12-15 Bayer Ag Proteinaseninhibitoren, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel.
EP0486001A1 (fr) 1990-11-13 1992-05-20 Mochida Pharmaceutical Co., Ltd. Fragments recombinants de l'inhibiteur urinaire de la trypsine et composition pharmaceutique
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
WO1997033996A2 (fr) 1996-03-11 1997-09-18 Bayer Corporation Bikunine humaine
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
BRPI0509367A (pt) * 2004-03-30 2007-09-11 Glaxo Group Ltd anticorpo, fragmento de ligação de antìgeno, composição farmacêutica, métodos de tratar um paciente humano afligido com uma doença ou distúrbio, de triar um anticorpo, e de detectar hosm em uma amostra biológica, uso de um anticorpo terapêutico ou fragmento de ligação de antìgeno, medicamento, vetor, polunucleotìdeo, célula hospedeira recombinante estavelmente transformada ou transfectada, e, processo para a fabricação de um anticorpo terapêutico
KR20070041781A (ko) * 2004-08-11 2007-04-19 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인 융합 단백질
CN103665168A (zh) * 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
EP1981519B1 (fr) 2005-12-29 2017-12-27 Dyax Corp. Inhibition de protease
US10407513B2 (en) * 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
AU2010246038A1 (en) * 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
EP3053932B1 (fr) * 2010-02-19 2020-07-22 Xencor, Inc. Nouvelles immunoadhésines ctla4-ig
CA2834626A1 (fr) * 2011-04-29 2012-11-01 University Of Washington Compositions a base de nuclease therapeutique et procedes associes
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
JP5855239B2 (ja) * 2012-04-23 2016-02-09 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
CN103044554B (zh) 2012-05-14 2014-08-27 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
CA2939639C (fr) * 2014-02-24 2023-01-24 Takeda Gmbh Proteines de fusion d'uti

Also Published As

Publication number Publication date
EA201691702A1 (ru) 2017-01-30
JP2019187427A (ja) 2019-10-31
AU2015218704A1 (en) 2016-09-22
AU2015218704B2 (en) 2019-05-02
RS58285B1 (sr) 2019-03-29
CN106232135A (zh) 2016-12-14
CN110092837B (zh) 2024-01-02
AU2019204448B2 (en) 2021-06-10
DOP2016000202A (es) 2016-12-15
PE20170257A1 (es) 2017-03-30
EP3110434B1 (fr) 2018-09-19
CR20160444A (es) 2017-04-21
AU2021225156B2 (en) 2022-11-24
KR20160141718A (ko) 2016-12-09
DK3110434T3 (en) 2019-01-14
NZ760008A (en) 2023-03-31
JP2023123763A (ja) 2023-09-05
EA202091567A1 (ru) 2021-07-30
SMT201800674T1 (it) 2019-01-11
EP3110434A1 (fr) 2017-01-04
US20220127334A1 (en) 2022-04-28
MX384070B (es) 2025-03-14
AU2023200875A1 (en) 2023-04-27
CY1120997T1 (el) 2019-12-11
ZA201606327B (en) 2019-01-30
AU2021225156A1 (en) 2021-09-30
CN110092837A (zh) 2019-08-06
NZ724196A (en) 2022-01-28
JO3729B1 (ar) 2021-01-31
PH12016501629A1 (en) 2017-02-06
PL3110434T3 (pl) 2019-01-31
KR102722304B1 (ko) 2024-10-28
AU2019204448A1 (en) 2019-07-11
US10351618B2 (en) 2019-07-16
MX2024000004A (es) 2024-02-20
US20160362475A1 (en) 2016-12-15
PH12016501629B1 (en) 2023-10-20
MA39347A1 (fr) 2018-06-29
KR20240155987A (ko) 2024-10-29
JP6938565B2 (ja) 2021-09-22
GEP20196970B (en) 2019-04-25
CN106232135B (zh) 2019-12-10
NZ760789A (en) 2023-03-31
SG10201708400QA (en) 2017-11-29
CL2016002136A1 (es) 2017-08-11
US20180072795A1 (en) 2018-03-15
CA3178241A1 (fr) 2015-08-27
JP2017512058A (ja) 2017-05-18
MY178774A (en) 2020-10-20
UA118866C2 (uk) 2019-03-25
BR112016019390B1 (pt) 2023-11-14
BR112016019390A2 (pt) 2017-10-24
PT3110434T (pt) 2018-12-19
ES2700149T3 (es) 2019-02-14
MX2016010950A (es) 2017-04-25
JP6574431B2 (ja) 2019-09-11
LT3110434T (lt) 2018-12-27
SG11201606691QA (en) 2016-09-29
US20200040062A1 (en) 2020-02-06
EA037256B1 (ru) 2021-02-26
TWI694084B (zh) 2020-05-21
TW201630931A (zh) 2016-09-01
KR20220151005A (ko) 2022-11-11
GEAP201814277A (en) 2018-12-25
MX2019013124A (es) 2020-08-31
AR101597A1 (es) 2016-12-28
KR102461210B1 (ko) 2022-10-31
JP2022002513A (ja) 2022-01-11
CA2939639A1 (fr) 2015-08-27
EP3443978A1 (fr) 2019-02-20
IL247321B (en) 2020-06-30
CA2939639C (fr) 2023-01-24
SI3110434T1 (sl) 2019-02-28
WO2015127391A1 (fr) 2015-08-27
US9856310B2 (en) 2018-01-02
IL247321A0 (en) 2016-09-29
ECSP16076535A (es) 2017-08-31
HRP20182029T1 (hr) 2019-02-08

Similar Documents

Publication Publication Date Title
MA39347A1 (fr) Protéines de fusion d'uti
IL268856A (en) Methods for purification of messenger rna
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
EP3679141C0 (fr) Méthodes et compositions pour inhiber l'expression de la ldha
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
EA202092435A2 (ru) Моноклональные антитела против bcma
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA40534B1 (fr) Inhibiteurs de mk2 et leurs utilisations
MA44008A (fr) 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MY193728A (en) Muscarinic receptor agonists
CY1119489T1 (el) Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
MX377774B (es) Formulaciones de proteinas.
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2016138538A3 (fr) Utilisation thérapeutique d'anticorps de liaison à l'intégrine
UA117779C2 (uk) Піразини як модулятори gpr6
MX2017008278A (es) Producto para el cuidado bucal y metodos para uso y fabricacion de este.
EA201691493A1 (ru) Замещенные n-арилпиридиноны
MA39230A1 (fr) Hexahydrofuropyrroles utilisés comme inhibiteurs de pde1
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
EA201692227A1 (ru) Производные сложных аминоэфиров
EP3387431A4 (fr) Systèmes, méthodes et compositions pour améliorer la spécificité de l'hybridation des acides nucléiques